Akebia Therapeutics, Inc. Stock News

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2 at 4:30 PM EST.

Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - ...

Vafseo® (vadadustat) Q3 2025 net product revenues grew to  $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality a...

Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 51,825 shares of Akebia's common stock on October 31, 2025.

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, prior to the open of financial markets.

Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA